Curriculum Vitae
Centro
Fac. de CC. de la SaludDepartamento
Ciencias Básicas de la SaludÁrea
FarmacologíaContacto
raquel.abalo@urjc.es-
Full professor of Pharmacology (December 2017-), Functional Coordinator of the Area of Pharmacology and Nutrition (January 2018-), and member of the URJC-IQM Commission (June 2018-). 4 Docentia (last one: 2015-17), 3 5-year teaching (last one: 2010-15) and 3 6-year research (last one: 2011-16) periods. Principal investigator of the Research Group NeuGut (URJC), interested in the physiopathology and pharmacology of the gastrointestinal (GI) tract. Our group was the first to characterize the enteric neuropathies occurring as sequelae of chemotherapy in preclinical models, and to determine the effects of cannabinoid agonists and antagonists to alleviate/prevent the associated GI motility alterations. GI motility alterations associated with aging, obesity, metabolic syndrome and diabetes and pharmacologic and nutritional therapeutic strategies are also being addressed in our lab. We have developed our own methods to evaluate GI tract motility in experimental animals, which have been adopted by other groups. We are interested in characterizing, using sophisticated computerized methods in collaboration with engineers (fluoroscopy, ultrasound vocalization), subtle alterations of GI motility and visceral sensitivity present in models of irritable bowel syndrome, metabolic syndrome and schizophrenia, and differences associated to gender. Close collaborators: Dr. Uranga (URJC), Dr. Fichna (U. Lodz, Poland), Dr. Nurgali (Victoria U., Australia), Dr. Soto-Montenegro (IiSGM, Madrid) and Dr. del Castillo (CIAL-CSIC-UAM, Madrid).
31 research projects (5 as Principal Investigator). 16 research contracts.54 articles in indexed journals (>80% as first/last/corresponding author), 7 articles in non-indexed journals, 5 chapters in national books, 4 chapters in international books, 1 e-book as guest editor for the journal Frontiers in Pharmacology. 13 invited talks at national (8) and international (5) meetings and 10 talks at different national (4) and international institutions (6). Supervisor of 3 PhD theses (2 with European Mention and Doctorate Extraordinary Award), 8 Final Master Assays and 39 Final Degree Assays, as well as several students from other national and international institutions during their degree practical/predoctoral training in our lab. Reviewer of more than 100 manuscripts in more than 40 indexed journals, 1 international book chapter and 20 research projects for international entities. Member of the editorial board of the journal Neurogastroenterology and Motility (from May 2018). Co-director of the Annual Madrid Meeting of Pharmacologists in 2017 (Farmadrid 26).
-
PLAN ASIGNATURA (2297) DOBLE GRADO EN CC. DE LA ACTIV. FISICA Y DEPORTE Y FISIOTERAPIA (ALCORCON) PATOLOGIA MEDICA (2031) GRADO EN CIENCIA Y TECNOLOGIA DE LOS ALIMENTOS (MOSTOLES) CULTURA Y EDUCACION ALIMENTARIA (2338) GRADO EN CIENCIA Y TECNOLOGIA DE LOS ALIMENTOS (MOSTOLES) CULTURA Y EDUCACION ALIMENTARIA (2035) GRADO EN ENFERMERIA (ALCORCON) FARMACOLOGIA. NUTRICION Y DIETETICA (2036) GRADO EN FISIOTERAPIA (ALCORCON) PATOLOGIA MEDICA (2229) GRADO EN INGENIERIA BIOMEDICA (FUENLABRADA) FARMACOLOGIA (2291) GRADO EN INGENIERIA BIOMEDICA (INGLES) (ALCORCON) PHARMACOLOGY (2000) GRADO EN MEDICINA (ALCORCON) FARMACOLOGIA (2037) GRADO EN ODONTOLOGIA (ALCORCON) FARMACOLOGIA
-
Fecha inicio: 01/07/17
Fecha fin: 30/09/17
Entidad financiadora: MINISTERIO DE EDUCACION, CULTURA Y DEPORTE
Referencia externa: PRX17/00373Investigador/es principal/es:
- Raquel Abalo Delgado
Investigador/es:
- Raquel Abalo Delgado
Fecha inicio: 09/02/16
Fecha fin: 08/02/18
Entidad financiadora: COMUNIDAD DE MADRID
Referencia externa: PEJ15/BIO/TL-0580Investigador/es principal/es:
- Raquel Abalo Delgado
Investigador/es:
- Raquel Abalo Delgado
Fecha inicio: 07/11/13
Fecha fin: 06/05/15
Entidad financiadora: UNIVERSIDAD REY JUAN CARLOS
Referencia externa: PRIN13_CS20Investigador/es principal/es:
- Gema Vera Pasamontes
Investigador/es:
- Gema Vera Pasamontes
- María Martínez Villaluengo
- Raquel Abalo Delgado
- María Rocio Girón Moreno
- José Antonio Uranga Ocio
Fecha inicio: 01/01/13
Fecha fin: 30/06/16
Entidad financiadora: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Referencia externa: SAF2012-40075-C02-01Investigador/es principal/es:
- María Isabel Martín Fontelles
Investigador/es:
- María Isabel Martín Fontelles
- Esperanza Milagrosa Herradón Pliego
- Carlos Goicoechea García
- David Pascual Serrano
- Nancy Antonieta Paniagua Lora
- María Rocio Girón Moreno
- José Antonio Uranga Ocio
- Eva María Sánchez Robles
- Visitación López-Miranda González
- Raquel Abalo Delgado
- Miguel Ángel Martínez García
- Cristina González Fernández
- Ana Bagües Arias
- Gema Vera Pasamontes
Fecha inicio: 01/01/12
Fecha fin: 30/04/16
Entidad financiadora: COMUNIDAD DE MADRID
Referencia externa: S2010/BMD-2308Investigador/es principal/es:
- María Isabel Martín Fontelles
Investigador/es:
- María Isabel Martín Fontelles
- Cristina González Fernández
- Eva María Sánchez Robles
- Esperanza Milagrosa Herradón Pliego
- David Pascual Serrano
- Visitación López-Miranda González
- Carlos Goicoechea García
- Ana Bagües Arias
- María Rocio Girón Moreno
- Miguel Ángel Martínez García
- Gema Vera Pasamontes
- Raquel Abalo Delgado
Fecha inicio: 01/01/10
Fecha fin: 30/06/13
Entidad financiadora: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Referencia externa: SAF2009-12422-C02-01Investigador/es principal/es:
- María Isabel Martín Fontelles
Investigador/es:
- María Isabel Martín Fontelles
- Mª Luz Serrano Rodríguez
- María Rocio Girón Moreno
- Esperanza Milagrosa Herradón Pliego
- Nancy A. Paniagua De Veizaga
- Susana Cáncer Pérez
- Elisa Burgos Gila
- Juan I. Gómez-Arnan Díaz Cañabate
- Visitación López-Miranda González
- Gema Vera Pasamontes
- David Pascual Serrano
- PABLO ANTONIO CABEZOS RODRIGUEZ
- Miguel Ángel Martínez García
- Ana Bagües Arias
- Raquel Abalo Delgado
- Carlos Goicoechea García
- Miriam Perera Sabio
- Eva María Sánchez Robles
- Cristina González Fernández
-
- Reseracher Id: H-3764-2015
- ORCID: 0000-0002-6726-8795
- Dialnet: 3320066
-
1. Uranga JA, Vera G, Abalo R (2018). Cannabinoid pharmacology and therapy in gut disorders.Biochem Pharmacol. 2018. pii: S0006-2952(18)30318-6. doi: 10.1016/j.bcp.2018.07.048 (in press) (Q1, D1).
2. López-Gómez L, Díaz-Ruano S, Girón R, López-Pérez AE, Vera G, Herradón E, López-Miranda V, Nurgali K, Martín-Fontelles MI, Uranga JA, Abalo R (2018). Preclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to rats. Neurogastroenterol Motil. 2018 Jul 4:e13399. doi: 10.1111/nmo.13399 (Q1).
3. Nurgali K, Jagoe RT, Abalo R, eds. (2018). Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Lausanne: Frontiers Media. doi: 10.3389/978-2-88945-482-2. ISBN: 978-2-88945-482-2. (Frontiers Research Topic - Frontiers in Pharmacology: Q1).
4. McQuade R, Petersen AC, Abalo R, Bornstein JC, Rybalka E, Nurgali K (2018). Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. Br J Pharmacol. 175(4):656-677. doi: 10.1111/bph.14114. (Q1, D1).
5. Herradón E, González C, Uranga JA, Abalo R, Martín-Fontelles MI, López-Miranda V (2017). Characterization of cardiovascular alterations induced by chronic cisplatin treatment in rats. Front Pharmacol. 8:196. doi: 10.3389/fphar.2017.00196. (Q1).
6. Vera G, López-Pérez AE, Uranga JA, Girón R, Martín-Fontelles MI, Abalo R(2017). Involvement of cannabinoid signaling in vincristine-induced gastrointestinal dysmotility in the rat. FrontPharmacol. 8:37. doi: 10.3389/fphar.2017.00037. (Q1).
7. Ramírez I, Pantrigo JJ, Sanz-Montemayor A, López-Pérez AE, Martín-Fontelles MI, Brookes SJH, Abalo R(2017). Computer vision-based diameter maps to study fluoroscopic recordings of small intestinal motility from conscious experimental animals. Neurogastroenterol Motil. 29(8). doi: 10.1111/nmo.13052. (Q1).
8. Uranga JA, García-Martínez JM, García-Jiménez C, Vera G, Martín-Fontelles MI, Abalo R(2017). Alterations of the small intestinal wall and motor function after repeated cisplatin in the rat. Neurogastroenterol Motil. 29 (7). doi: 10.1111/nmo.13047. (Q1).
9. Abalo R, Uranga JA, Pérez-García I, de Andrés R, Girón R, Vera G, López-Pérez AE, Martín-Fontelles MI (2017). May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat. Neurogastroenterol Motil. 29 (3). doi: 10.1111/nmo.12952. (Q1).
10. Girón R, Pérez-García I, Abalo R(2016). X-ray analysis of gastrointestinal motility in conscious mice. Effects of morphine and comparison with rats. Neurogastroenterol Motil. 28 (1): 74-84. doi: 10.1111/nmo.12699 (Q1).